+587.9%
WDC vs MRNA
-20.0%
+607.9%
-64.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.7% | -4.8% | +6.6% | +2.0% |
| 7D | -8.0% | -20.9% | +12.9% | -6.7% |
| 30D | -18.2% | -13.3% | -4.9% | -17.5% |
| 3M | -41.9% | +212.6% | -254.5% | -48.5% |
| 6M | -37.1% | +309.0% | -346.2% | -48.0% |
| YTD | +67.5% | +567.3% | -499.8% | +25.3% |
| 1Y | +88.9% | +689.7% | -600.8% | +36.8% |
| 3Y | +721.8% | +157.4% | +564.4% | +575.6% |
| 5Y | +587.9% | -21.7% | +609.6% | +515.9% |
| All | +587.9% | -20.0% | +607.9% | +515.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling